Boehringer Ingelheim International Gmbh

Abdulsalam Shaaban

Pankaj Gupta

Priyanka Gupta

Klaus-Peter Kuenkele

Paul Adam

Karl-Heinz Heider

Elinborg Ostermann

Ivo Lorenz

Stephen R Comeau

Philip Nicholas Gorman

Renate Konopitzky

Fei Han

Andreas Wernitznig

Sandeep Kumar

Helen Haixia Wu

Dongmei Liu

Srinath Kasturirangan

David Weismann

David S Young

David A Blair

Mouhamadou Lamine Mbow

Joseph A Mozdzierz

Guangwei Yang

Taneisha Ann-Tanara Mack

Aaron Timothy Karlak

Nicole K Garaffa

Kerry L M Ralph

Miguel E Moreno-Garcia

Della M White

The present invention relates to new anti-PD-1 (Programmed cell death 1) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.

Anti-PD-1 antibodies

The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Tri-specific binding molecules

Growing community of inventors

Ridgefield, CT, United States of America

Abdulsalam Shaaban